Ji-Won Kim1, Jun Sik Yoon2, Eun Jin Kim3, Hyo-Lim Hong4, Hyun Hee Kwon4, Chi Young Jung3, Kyung Chan Kim3, Yu Sub Sung5,6, Sung-Hoon Park1, Seong-Kyu Kim1, Jung-Yoon Choe1. 1. Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Republic of Korea. 2. Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Republic of Korea. 3. Division of Pulmonology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Republic of Korea. 4. Division of Infectious Diseases, Department of Internal Medicine, Daegu Catholic University School of Medicine, Republic of Korea. 5. Clinical Research Center, Asan Medical Center, Seoul, Republic of Korea. 6. Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: The impact of sarcopenia on clinical outcomes of coronavirus disease 2019 (COVID-19) is not clearly determined yet. We aimed to investigate the association between baseline sarcopenia and clinical outcomes in patients with COVID-19. METHODS: All hospitalized adult patients with COVID-19 who had baseline chest computed tomography (CT) scans at a Korean university hospital from February 2020 to May 2020 were included. The main outcome was time from hospital admission to discharge. Death was considered as a competing risk for discharge. Baseline skeletal muscle cross-sectional area at the level of the 12th thoracic vertebra was measured from chest CT scans. The lowest quartile of skeletal muscle index (skeletal muscle cross-sectional area divided by height-squared) was defined as sarcopenia. RESULTS: Of 121 patients (median age, 62 years; 44 men; 29 sarcopenic), 7 patients died and 86 patients were discharged during the 60-day follow-up. Patients with sarcopenia showed a longer time to discharge (median, 55 vs 28 days; p < .001) and a higher incidence of death (17.2% vs 2.2%; p = .004) than those without sarcopenia. Baseline sarcopenia was an independent predictor of delayed hospital discharge (adjusted hazard ratio [aHR], 0.47; 95% confidence interval [95% CI], 0.23-0.96), but was not independently associated with mortality in patients with COVID-19 (aHR, 3.80; 95% CI, 0.48-30.26). The association between baseline sarcopenia and delayed hospital discharge was consistent in subgroups stratified by age, sex, comorbidities, and severity of COVID-19. CONCLUSIONS: Baseline sarcopenia was independently associated with a prolonged hospital stay in patients with COVID-19. Sarcopenia could be a prognostic marker in COVID-19.
BACKGROUND: The impact of sarcopenia on clinical outcomes of coronavirus disease 2019 (COVID-19) is not clearly determined yet. We aimed to investigate the association between baseline sarcopenia and clinical outcomes in patients with COVID-19. METHODS: All hospitalized adult patients with COVID-19 who had baseline chest computed tomography (CT) scans at a Korean university hospital from February 2020 to May 2020 were included. The main outcome was time from hospital admission to discharge. Death was considered as a competing risk for discharge. Baseline skeletal muscle cross-sectional area at the level of the 12th thoracic vertebra was measured from chest CT scans. The lowest quartile of skeletal muscle index (skeletal muscle cross-sectional area divided by height-squared) was defined as sarcopenia. RESULTS: Of 121 patients (median age, 62 years; 44 men; 29 sarcopenic), 7 patientsdied and 86 patients were discharged during the 60-day follow-up. Patients with sarcopenia showed a longer time to discharge (median, 55 vs 28 days; p < .001) and a higher incidence of death (17.2% vs 2.2%; p = .004) than those without sarcopenia. Baseline sarcopenia was an independent predictor of delayed hospital discharge (adjusted hazard ratio [aHR], 0.47; 95% confidence interval [95% CI], 0.23-0.96), but was not independently associated with mortality in patients with COVID-19 (aHR, 3.80; 95% CI, 0.48-30.26). The association between baseline sarcopenia and delayed hospital discharge was consistent in subgroups stratified by age, sex, comorbidities, and severity of COVID-19. CONCLUSIONS: Baseline sarcopenia was independently associated with a prolonged hospital stay in patients with COVID-19. Sarcopenia could be a prognostic marker in COVID-19.
Authors: Hakan Kardas; Maximilian Thormann; Caroline Bär; Jazan Omari; Andreas Wienke; Maciej Pech; Alexey Surov Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Madu N Soares; Moritz Eggelbusch; Elie Naddaf; Karin H L Gerrits; Marike van der Schaaf; Bram van den Borst; W Joost Wiersinga; Michele van Vugt; Peter J M Weijs; Andrew J Murray; Rob C I Wüst Journal: J Cachexia Sarcopenia Muscle Date: 2022-01-07 Impact factor: 12.910
Authors: R Menozzi; F Valoriani; F Prampolini; F Banchelli; E Boldrini; F Martelli; S Galetti; R Fari'; S Gabriele; P Palumbo; D Forni; M Pantaleoni; R D'Amico; A R Pecchi Journal: Clin Nutr ESPEN Date: 2021-12-07